Introduction
============

As antibiotic use has increased, antibiotic resistance has become a concern in the community. Due to resistance, it is difficult to choose early empiric antibiotics for urinary tract infections (UTI), which are a common infection in the community. In particular, extended-spectrum β-lactamase-producing *Enterobacteriaceae* (ESBL-PE) are co-resistant to other non-β-lactam antimicrobials \[[@B1][@B2]\]. As a result, treatment of community-acquired UTI (CA-UTI) has becoming challenging for clinicians \[[@B3][@B4]\].

The domestic UTI guideline, which was revised in 2011, recommended fluoroquinolones as a primary choice, and this reflected local community resistance until 2008. A study published after the revision of the guideline showed a resistance rate to fluoroquinolones over 20%, which is the limit of the local resistance rate recommended by the Infectious Diseases Society of America (IDSA) for empirical treatment \[[@B5][@B6]\]. That study also showed that ESBL-PE accounted for 8.7% of CA-UTI cases in 2011 \[[@B5]\]. Given the global trend of increasing ESBL-PE, the proportion is likely much higher recently in Korea \[[@B7]\]. Thus, there is a need to re-evaluate empiric antibiotics for CA-UTIs.

Despite of the need for data on the current antibiotic susceptibility pattern for empirical treatment choices, there is a lack of up-to-date susceptibility data for CA-UTIs in Korea. Furthermore, data on antibiotics that can replace carbapenems in ESBL-PE are needed in cases where carbapenems should be conserved, due to concern for carbapenem-resistant *Enterobacteriaceae* (CRE). We investigated resistance trends for *Enterobacteriaceae* in CA-UTI over a five-year period to identify suitable first-line antibiotics. In addition, we evaluated triable alternatives to carbapenems in ESBL-PE.

Materials and Methods
=====================

1. Study design and study population {#sec1}
------------------------------------

This was a retrospective study to assess the antimicrobial susceptibility of CA-UTI causative pathogens. This study was conducted in a 578-bed university hospital in Seoul from January 2012 to December 2016. We reviewed the medical records of patients diagnosed with UTIs based on the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes (urinary tract infection, N390; acute cystitis, N300; acute pyelonephritis, N10.03; and acute prostatitis, N410) in the emergency room and outpatient clinic. Among patients with that diagnosis, patients that received treatment in the outpatient clinics and emergency room and were treated in the ward were all included. We included adults over 19 with urine culture from a voided mid-stream urine specimen. Causative organisms from urine cultures were identified. Only those pathogens identified for the first time were included.

2. Definition and data collection {#sec2}
---------------------------------

Among cases diagnosed within the first 48 hours of hospitalization, we excluded patients if any of the following criteria were present: (1) The patient received intravenous therapy, wound care, or specialized nursing care at home or in an outpatient clinic, or received renal dialysis in the previous 30 days before infection, including urinary or digestive tract endoscopy or other invasive procedures, (2) The patient attended a hospital or hemodialysis clinic within 30 days before infection, or (3) The patient was hospitalized for \>2 days in an acute care hospital or the patient resided in a nursing home or long-term care facility within the previous 90 days \[[@B8][@B9]\].

Likelihood of inadequate therapy (LIT) is the frequency of inadequately treated patients for each antibiotic and drug-resistant strain. This score calculates the numerically recommended rank of empiric antibiotics, considering the frequency of pathogens and resistance rates. Organism-specific LIT is the percentage of drug resistance for each bacterium in a local pool of patients divided by 100. For example, if 50% of *Escherichia coli* were resistant to cefepime, then the *E-coli*-specific LIT for cefepime is two (100/50%). This value implies that two patients with *E. coli* infection would need to be treated with cefepime for one to be inadequately treated. For pathogens with 0% resistance, a LIT of 100 is assigned. Syndrome-specific LIT is the frequency of inadequately treated patients with the syndrome. The LIT of each pathogen is multiplied by its frequency of occurrence in a given indication. These multiplied LIT values are summed and then divided by the cumulative percentage rate of the pathogen \[[@B10][@B11]\].

3. Microbiologic data {#sec3}
---------------------

Etiologic pathogens were determined when ≥10^5^ colony-forming units/mL of organisms were cultured from midstream urine. Microbial identification was carried out using the Vitek-2 system (bioMerieux, Inc., Durham, NC, USA). Vitek-2 cards containing an ESBL test were used. Antimicrobial susceptibility to amikacin, ampicillin, amoxicillin-clavulanic acid, aztreonam, cefepime, cefotaxime, cefoxitin, ceftazidime, fluoroquinolones, ertapenem, gentamicin, imipenem, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole (TMP/SMX) was tested in *Enterobacteriaceae*. Susceptibility was determined by the broth microdilution test, according to the guidelines prescribed by Clinical and Laboratory Standards Institute \[[@B12][@B13]\]. Isolates showing intermediate antimicrobial susceptibility were considered to be resistant. Data was analyzed dividing into patients treated in the outpatient clinic and in admission.

4. Statistical analysis {#sec4}
-----------------------

Statistical significance was assessed via the Chi-square test or Fisher\'s exact test for the categorical variables. Linear regression was used to assess the trends of the yearly antimicrobial resistance and UTI of ESBL-PE. A *P-*value of \<0.05 was considered statistically significant. Statistical analysis was performed with IBM SPSS ver. 20 (IBM SPSS Inc., Armonk, NY, USA).

5. Ethics statement {#sec5}
-------------------

The study was approved by the Institutional Review Board of Hallym University Kangnam Sacred Heart Hospital in Korea (IRB\#: 2016-12-177).

Results
=======

During the study period, 2,208 patients were diagnosed with a CA-UTI and 1,605 urine specimens were analyzed. 471 specimens in which the causative pathogen could not be identified were excluded. Thus 1,134 (70.7%, 1,134/1,605) cases were included in this study. Among study population, 807 patients (71.2%) were treated in outpatient clinic and 327 patients (28.8%) were in admission.

The most common causative pathogen was *E. coli,* which caused 911 (80.3%) cases ([Table 1](#T1){ref-type="table"}). Gram negative bacteria accounted for 89.0% (n = 1,009) and 998 (88.0%) cases were *Enterobacteriaceae*. After *E. coli*, *Klebsiella* species (n = 38, 3.4%) was the most common pathogen, followed by *Enterobacter* species (n = 27, 2.4%) and *Proteus* species (n = 11, 1.0%) among gram negative bacteria. Among gram positive bacteria (n = 125, 11.0%), *Streptococcus* species accounted for the highest proportion at 7.8% (n = 89), followed by *Enterococcus* species (n = 27, 2.4%) and *Staphylococcus aureus* (n = 6, 0.5%).

###### Causative pathogens of community-acquired urinary tract infection.

![](ic-49-184-i001)

  Pathogens                         Community-acquired urinary tract infection, n (%)
  --------------------------------- ---------------------------------------------------
  Gram negative bacteria            1,009 (89.0)
   *Escherichia coli*               911 (80.3)
   *Klebsiella* species             38 (3.4)
   *Enterobacter* species           27 (2.4)
   *Proteus* species                11 (1.0)
   *Citrobacter* species            4 (0.4)
   *Pseudomonas* species            8 (0.7)
   *Serracia marcescens*            3 (0.3)
   Others                           7 (0.6)
  Gram positive bacteria            125 (11.0)
   *Streptococcus* species          89 (7.8)
   *Enterococcus* species           27 (2.4)
   *Staphylococcus aureus*          6 (0.5)
   *Staphylococcus saprophyticus*   3 (0.3)
  Total                             1,134 (100)

[Table 2](#T2){ref-type="table"} shows mean resistance rates of *Enterobacteriaceae* to antimicrobial agents. Overall, amikacin, ertapenem and imipenem showed the lowest resistance rates at 0.1%, 0.2% and 0.3%, respectively. Cefepime (2.4%), piperacillin-tazobactam (3.5%), ceftazidime (3.9%), and aztreonam (6.0%) had lower than 10% resistance rates. Resistance rates to cefoxitin and cefotaxime were 10.1% and 13.5%, respectively. Gentamicin (20.1%), amoxicillin-clavulanic acid (20.6%), and fluoroquinolones (23.2%) showed resistance rates higher than 20%. TMP/SMX and ampicillin showed the highest resistance rates, at 31.7% and 64.6%. Outpatients accounted for 69.5% (n = 694) and hospitalized patients accounted for 30.5% (n = 304) in *Enterobacteriaceae*. Resistance rates were similar between hospitalized and outpatient patients ([Table 2](#T2){ref-type="table"}). Resistance rates to piperacillin-tazobactam, ertapenem and TMP/SMX were higher in admitted patients with significance (*P* = 0.040, 0.024 and 0.020, respectively). On the other hand, imipenem showed a higher resistance rate in outpatients with significance (*P* = 0.024). The number of resistant cases in ertapenem, imipenem and piperacillin-tazobactam was quite small. Therefore it was difficult to compare resistance rates between outpatients and hospitalized patients. The resistance rate of cefotaxime was higher in hospitalized patients and that of fluoroquinolone was lower in outpatients but without significance (*P* = 0.706 and 0.082). The changes in the antimicrobial resistance rates of *Enterobacteriaceae* over the five-year period are shown in [Table 3](#T3){ref-type="table"}. Resistance rates of ertapenem, imipenem and piperacillin-tazobactam showed a decreasing tendency with significant according to year (*P* \<0.001, \<0.001 and \<0.001). However, resistance cases for ertapenem and imipenem were only found in 2014 and the number of that for piperacillin-tazobactam was quite small, it was difficult to assess the trend during five years. Although amoxicillin-clavulanic acid, cefotaxime, and aztreonam also showed increasing trends, there was no statistical significance (*P* = 0.298, 0.220, and 0.362, respectively). Resistance rates to ampicillin and fluoroquinolones showed a decreasing pattern, but without statistical significance (*P* = 0.222 and 0.546, respectively). During a five-year period, a total of 118 ESBL-PE (11.3%) were identified. The proportion of ESBL-PE was 10.3% in 2012, 8.7% in 2013, 12.2% in 2014, 11.8% in 2015, and 13.8% in 2016 ([Fig. 1](#F1){ref-type="fig"}). Overall, this tended to increase during the study period, but there was no statistical significance (*P* = 0.255).

###### Mean antimicrobial resistance rates of *Enterobacteriaceae* according to outpatient clinic and hospitalization during a five-year period.
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  ------------------------------------------------------------------------------------------------------------------
  Resistant antibiotics   Total (n = 998)\   Outpatient clinic (n = 694)\   Hospitalization (n = 304)\   *P*-value
                          n (%)              n (%)                          n (%)                        
  ----------------------- ------------------ ------------------------------ ---------------------------- -----------
  AMP                     647 (64.6)         446 (64.3)                     199 (65.5)                   0.716

  AMC                     207 (20.7)         146 (21.0)                     61 (20.1)                    0.728

  TZP                     33 (3.5)           20 (2.9)                       13 (4.3)                     0.040

  FOX                     102 (10.2)         69 (9.9)                       33 (10.9)                    0.661

  CTX                     135 (13.5)         92 (13.3)                      43 (14.1)                    0.706

  CAZ                     39 (3.9)           28 (4.0)                       11 (3.6)                     0.755

  FEM                     24 (2.4)           15 (2.2)                       9 (3.0)                      0.448

  ATM                     60 (6.0)           43 (6.2)                       17 (5.6)                     0.712

  EPM                     2 (0.2)            1 (0.1)                        1 (0.3)                      0.024

  IPM                     4 (0.3)            4 (0.4)                        0 (0)                        0.028

  FQ^a^                   232 (23.2)         172 (24.8)                     60 (19.7)                    0.082

  GEN                     201 (20.1)         137 (19.7)                     64 (21.1)                    0.634

  AMK                     1 (0.1)            1 (0.1)                        0 (0)                        1.000

  TMP/SMX                 316 (31.7)         204 (29.4)                     112 (36.8)                   0.020
  ------------------------------------------------------------------------------------------------------------------

^a^Ciprofloxacin and/or levofloxacin

AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; EPM, ertapenem; IPM, imipenem; FQ, fluoroquinolones; GEN, gentamicin; AMK, amikacin; TMP/SMX, trimethoprime-sulfamethoxazole

###### Trends in antimicrobial resistance rates of *Enterobacteriaceae* during the study period (n = 998).
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  Antibiotics   Susceptibility rates, n (%)   *P*-value                                           
  ------------- ----------------------------- ------------ ------------ ------------ ------------ ---------
  AMP           122 (67.4)                    144 (66.7)   119 (64.7)   132 (61.1)   128 (63.7)   0.222
  AMC           32 (17.7)                                  44 (23.9)    51 (23.6)    40 (19.9)    0.298
  TZP           5 (4.1)                       6 (2.8)      6 (3.3)      6 (2.8)      10 (5.0)     \<0.001
  FOX           16 (8.8)                      22 (10.2)    30 (16.3)    19 (8.8)     15 (7.5)     0.498
  CTX           19 (10.5)                     27 (12.5)    31 (16.8)    27 (12.5)    31 (15.4)    0.220
  CAZ           3 (1.7)                       6 (2.8)      6 (7.1)      7 (3.2)      10 (5.0)     0.117
  FEM           0 (0)                         4 (1.9)      7 (3.8)      6 (2.8)      7 (3.5)      0.027
  ATM           8 (4.4)                       11 (5.1)     16 (8.7)     11 (5.1)     14 (7.0)     0.362
  EPM           0 (0)                         0 (0)        2 (1.1)      0 (0)        0 (0)        \<0.001
  IPM           0 (0)                         0 (0)        3 (1.6)      0 (0)        0 (0)        \<0.001
  FQ^a^         43 (23.8)                     48 (22.2)    52 (28.3)    46 (21.3)    43 (21.4)    0.546
  GEN           40 (22.1)                     42 (19.4)    49 (26.6)    32 (14.8)    38 (18.9)    0.214
  AMK           0 (0)                         1 (0.5)      0 (0)        0 (0)        0 (0)        0.458
  TMP/SMX       58 (32.0)                     74 (34.3)    60 (32.6)    62 (28.7)    62 (30.8)    0.419

^a^Ciprofloxacin and/or levofloxacin

AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; EPM, ertapenem; IPM, imipenem; FQ, fluoroquinolones; GEN, gentamicin; AMK, amikacin; TMP/SMX, trimethoprime-sulfamethoxazole

![Yearly proportion of extended-spectrum β-lactamase-producing *Enterobacteriaceae* during the study period.](ic-49-184-g001){#F1}

Antimicrobial susceptibility rates in ESBL-PE are shown in [Figure 2](#F2){ref-type="fig"}. Imipenem and ertapenem had high susceptibility rates at 100% and 99.2%, respectively. Amikacin showed the same susceptibility rate as ertapenem. Piperacillin-tazobactam showed a relatively high susceptibility rate of 94.3%, while the susceptibility rate to cefepime was 82.0%. Other antimicrobial agents such as cefoxitin, amoxicillin-clavulanic acid, gentamicin, aztreonam, TMP/SMX, and fluoroquinolones, had over 20% resistance rates.

![Mean antimicrobial susceptibility rates of Extended spectrum β-lactamase-producing *Enterobacteriaceae* during the study period (n = 118).](ic-49-184-g002){#F2}

To reflect more recent trends, the LIT was calculated with data from the past two years from *Enterobacteriaceae* in CA-UTIs ([Table 4](#T4){ref-type="table"}). Organism-specific LIT was different by pathogens. For *E. coli*, resistance was 0% for ertapenem, imipenem and amikacin and thus represented by an organism-specific LIT of 100. Ampicillin, TMP/SMX and fluoroquinolones showed the lowest organism-specific LIT as 2, 3.2 and 4.4. For *Klebsiella* species, organism-specific LIT was 100 for ertapenem, imipenem and amikacin and the lowest for ampicillin as 1. Overall, UTI LIT was ranked first for ertapenem, imipenem, and amikacin, with LITs of 100. Except carbapenems, cefepime and piperacillin-tazobactam were ranked highest, with LITs of 34.3 and 31.7, respectively, followed by ceftazidime, with a LIT of 27.0. Aztreonam, cefoxitin, and cefotaxime formed an intermediate group with LITs of 18.1, 16.7, and 10.5, respectively. The LIT value of fluoroquinolones and TMP/SMX was 8.2 and 7.0, respectively. The lowest rank was ampicillin, with a LIT of 1.9. In the outpatient clinic, cefoxitin (LIT = 23.5) ranked higher than aztreonam (LIT = 16.9) followed by cefotaxime, amoxicillin-clavulanic acid and gentamicin with LITs of 11.5, 9.8 and 9.8 respectively. The LIT value of fluoroquinolones, TMP/SMX and ampicillin was 9.2, 8.6 and 2.0 fell into the lower group. There were some differences within hospitalized patients. Aztreonam was ranked higher than outpatients and the LIT value was same with ceftazidime as 24.5. Amoxicillin-clavulanic acid was ranked lower than outpatients with LIT of 4.8.

###### Likelihood of inadequate therapy (LIT) among *Enterobacteriaceae* in community-acquired urinary tract infections (CA-UTI) over the past two years.
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  Rank   Total                           Outpatient clinic   Hospitalization                                                                  
  ------ ------------------------------- ------------------- ----------------------------------------- ------ ------------------------------- ------
  1      Ertapenem, Imipenem, Amikacin   100                 Ertapenem, Imipenem, Amikacin             100    Ertapenem, Imipenem, Amikacin   100
  2      Cefepime                        34.3                Cefepime                                  38.9   Cefepime                        33.3
  3      Piperacillin-tazobactam         31.7                Piperacillin-tazobactam                   34.1   Piperacillin-tazobactam         29.0
  4      Ceftazidime                     27.0                Ceftazidime                               30.7   Ceftazidime, aztreonam          24.5
  5      Aztreonam                       18.1                Cefoxitin                                 23.5   Cefoxitin                       12.5
  6      Cefoxitin                       16.7                Aztreonam                                 16.9   Cefotaxime                      9.4
  7      Cefotaxime                      10.5                Cefotaxime                                11.5   Gentamicin                      8.1
  8      Gentamicin                      8.7                 Amoxicillin-Clavulanic acid, Gentamicin   9.8    Fluoroquinolones^b^             7.1
  9      Fluoroquinolones^b^             8.2                 Fluoroquinolones^b^                       9.2    Amoxicillin-Clavulanic acid     4.8
  10     Trimethoprim-Sulfamethoxazole   7.0                 Trimethoprim-Sulfamethoxazole             8.6    Trimethoprim-Sulfamethoxazole   4.7
  11     Amoxicillin-Clavulanic acid     6.4                 Ampicillin                                2.0    Ampicillin                      1.6
  12     Ampicillin                      1.9                                                                                                  

^a^LIT of *Enterobacteriaceae* in CA-UTI: The LIT ^c^ of each pathogen is multiplied by its frequency of occurrence in a given indication. These multiplied LIT values are summed and then divided by the cumulative percentage rate of the pathogen (n = 89.9%)

^b^Ciprofloxacin and/or levofloxacin

^c^Percentage of drug resistance for each bacterium in a local pool of patients divided by 100; For pathogens with 0% resistance, a LIT of 100 was assigned.

Discussion
==========

CA-UTIs caused by resistant strains have been increasing worldwide, including ESBL-PE \[[@B3][@B7][@B14]\]. Common empiric antibiotics are not effective against resistant pathogens and are likely to lead treatment failure. In order to select appropriate antibiotics, it is necessary to understand community resistance rates. Korean CA-UTI epidemiology data are only up to date until 2011; therefore, there is a need to understand more recent trends. In this study, we analyzed changes in resistance rates of *Enterobacteriaceae* from the community over the past five years.

IDSA recommends TMP/SMX as an empiric antibiotic treatment for UTI \[[@B6]\]. However, it was not recommended as an empiric treatment in Korea due to a resistance rate over 30% \[[@B15]\]. In our study, the resistance rate to TMP/SMX was 31.7%, which supports the Korean UTI guidelines; these recommend fluoroquinolones as a primary choice. From 2012 to 2016, the mean antimicrobial resistance rate of fluoroquinolones was 23.2% in this study. One study examined the epidemiology of CA-acute pyelonephritis from 2010 to 2011 and reported that the resistance rate to fluoroquinolones was 22.1% \[[@B5]\]. Resistance rates have been relatively stable since then; in addition, except for 2014, resistance rates to fluoroquinolones decreased during this period, and the resistance rate was 21.4% in 2016. IDSA recommends that empiric antibiotics not be used in communities with resistance rates \>20% \[[@B6]\]. Considering overall resistance rates, fluoroquinolone use may be limited for primary therapy. However, due to high urinary tract concentrations and relatively stable resistance rates, this antibiotic class is unlikely to be completely excluded from primary treatment \[[@B16]\]. Nevertheless, we should be careful about the use of fluoroquinolones as a primary choice. Cefotaxime showed a resistance rate of 13.5%. Simply considering resistance rates, cefotaxime would be a primary choice for empiric antibiotics for CA-UTIs in Korea. However, there is concern for an increased resistance rate due to increasing use of cefotaxime. The resistance rate to cefotaxime was increased, compared to a rate of 8.3% from 2010 to 2011 \[[@B5]\]. In this study, resistance to cefotaxime increased from 10.5% in 2012 to 15.4% in 2016. Assessment of adequate antibiotic use through continuous monitoring of resistance rates is needed.

ESBL-PE showed an overall increasing pattern in CA-UTIs. In 2016, the rate of ESBL-PE infection was 13.8%, compared to 8.7% from 2010 to 2011 \[[@B5]\]. The proportion of ESBL-PE in the community is high, and this is a global trend \[[@B7]\]. Therefore, it is important to determine who should be treated initially for ESBL-producing pathogens. Although factors such as recent admission history, residence in a long-term care facility, and urethral catheterization were suggested as risk factors, most factors were correlated with healthcare centers. In the community, previous antibiotics use should be considered for treating ESBL-PE especially quinolones or second generation cephalosporins \[[@B17]\]. The male sex also showed an increased risk for ESBL-PE infections in some studies. Advanced age, diabetes mellitus and prostatic disease was considered as risk factors in community-acquired pathogens \[[@B2][@B18][@B19]\]. Interestingly, recreational freshwater swimming the past year was considered as a risk factor in one study \[[@B20]\]. Although there are no definite guidelines for selecting patients for treating ESBL-PE, using susceptible antimicrobials for ESBL-producing pathogens in patients with more risk factors will hit the mark the pathogen. There is a conflict about the prognosis of inappropriate empirical therapy. Some studies reported that inadequate empiric therapy did not affect mortality \[[@B21]\]. However, recent studies showed the association between inadequate empiric therapy and higher mortality \[[@B22][@B23]\]. There are some concerns about toxicity, cost and resistance for using empiric therapy to ESBL-PE such as carbapenem. An appropriate empiric therapy could reduce the length of stay and duration of symptoms \[[@B24]\]. Further study of empiric therapy for UTI is needed because most studies were performed in blood stream infection. Although the result of inadequate empiric therapy was contradictory, we should keep in mind that adequate empiric therapy could be critical for elderly or severely ill patients. There need to be effort to determine appropriate empirical antibiotics.

The first-line therapy for ESBL-PE is carbapenems \[[@B25]\]. The risk of CRE has increased with carbapenem use; therefore, attention to carbapenem alternatives has been growing. Some observational studies have examined the use of non-carbapenem alternatives for treatment of ESBL-PE \[[@B26][@B27][@B28][@B29][@B30]\]. We also investigated the susceptibility rates of non-carbapenem antibiotics in ESBL-PE. Amikacin showed a high *in vitro* susceptibility rate of 99.2%, and piperacillin-tazobactam also showed a high susceptibility rate of 94.3%. One study reported that susceptible non-carbapenems had a similar clinical improvement rate for ESBL-PE in UTIs \[[@B31]\]. We could treat with amikacin and piperacillin-tazobactam empirically in cases with risk factors for ESBL-PE infection. Although amikacin showed the same level of susceptibility as ertapenem, clinicians avoid aminoglycosides due to concern for nephrotoxicity. The therapeutic efficacy of amikacin in ESBL-PE has not been investigated sufficiently and should be examined. It may be challenging to use piperacillin-tazobactam in severe cases with a high inoculum effect \[[@B25]\]. Susceptibility to piperacillin-tazobactam ranged from 58.6% to 94.2% in CA-UTIs due to ESBL-PE UTI in Korea \[[@B5][@B30][@B32]\]. The reason for this wide range is unclear, but may reflect different regional rates. Therefore, the use of piperacillin-tazobactam as an empiric antibiotic in patients at risk for ESBL-PE infection should take regional susceptibility rates into account.

We analyzed the LIT with data from the past two years. LIT was a helpful marker to determine whether empiric treatment reflects resistance rates and the frequency of pathogens in rank order \[[@B10][@B11]\]. Carbapenems were the highest ranked. Fluoroquinolones were 11th out of 14 antibiotics, with a LIT value of 8.2; therefore, fluoroquinolones should be cautiously used as empiric CA-UTI treatment. Cefotaxime was ranked higher than fluoroquinolones, with a LIT of 10.5. Cefotaxime would be considered as a primary treatment for CA-UTI, reflecting its rank in this study. In the outpatient clinic, fluoroquinolones should be cautious due to relatively lower ranking. Third generation cephalosporin could be a best choice reflecting highest ranking among antimicrobial agents which could be used orally. Amoxicillin-clavulanic acid could be an alternative. Cefotaxime was also a good choice in hospitalized patients with a LIT value of 9.4. However, amoxicillin-clavulanic acid showed a lower rank than outpatient clinic at 12th and the value of LIT was at 4.8. Considering the rank of fluoroquinolones in hospitalized patients, choosing fluoroquinolones as an empiric therapy also should be careful in admitting patients.

There are some limitations to our study. First, we retrospectively collected data through electronic medical records and chart review. It was difficult to obtain all characteristics for analyzing risk factors such as comorbidity, previous antibiotics use and history of recurrent UTI due to unrecorded information. Also, in defining CA-UTI, healthcare-associated UTI might be classified as CA-UTI. Second, this study was conducted only in a single center. Therefore, it is difficult to reflect the overall characteristics of Korea. This study suggests the need for further large-scale nationwide surveillance on the epidemiology of CA-UTI. Finally, resistance rates are likely overestimated because this study was performed at a university hospital. However, as this study was conducted at a secondary hospital which could be visited without referral, it might reflect the community well.

In conclusion, early empirical treatment with fluoroquinolones in CA-UTI should be carefully considered due to the high resistance rate. The proportion of ESBL-PE in CA-UTI has increased to a high level in Korea. Amikacin and piperacillin-tazobactam can be considered for empiric treatment as alternatives to carbapenems in patients at risk for ESBL-PE .
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